{"id":"NCT01968551","sponsor":"Gilead Sciences","briefTitle":"Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults","officialTitle":"A Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-03","primaryCompletion":"2015-07-21","completion":"2016-07-09","firstPosted":"2013-10-24","resultsPosted":"2016-11-01","lastUpdate":"2018-11-16"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1","HIV Infections","Acquired Immunodeficiency Syndrome"],"interventions":[{"type":"DRUG","name":"E/C/F/TAF","otherNames":["GenvoyaÂ®"]},{"type":"DRUG","name":"DRV","otherNames":[]},{"type":"DRUG","name":"Baseline DRV- containing ARV regimen","otherNames":[]}],"arms":[{"label":"Cohort 1","type":"EXPERIMENTAL"},{"label":"Cohort 2, Treatment Group 1","type":"EXPERIMENTAL"},{"label":"Cohort 2, Treatment Group 2","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) plus darunavir (DRV) relative to current antiretroviral regimens (ARV) in virologically suppressed, HIV-1 positive participants with HIV-1 RNA \\<50 copies/mL at Week 24.\n\nThis study consists of 48 weeks of open-label phase followed by an optional Extension Phase in which all the participants will receive E/C/F/TAF+DRV.","primaryOutcome":{"measure":"Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Cohort 2: E/C/F/TAF+DRV","deltaMin":96.6,"sd":null},{"arm":"Cohort 2: Stay on Baseline Regimen (SBR)","deltaMin":91.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.23"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":14},"locations":{"siteCount":62,"countries":["United States","Canada"]},"refs":{"pmids":["27753684"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":21},"commonTop":["Upper respiratory tract infection","Sinusitis","Back pain","Bronchitis","Headache"]}}